Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-02T19:05:59.345Z.
Calculation as of: 2026-10-02T19:05:59.345Z.
Quote observation: 2026-10-02T19:05:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Recursion Pharmaceuticals, Inc.
Market Cap
$2.13B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.49B
Price/OCF Ratio
N/A
TTM Avg
39.43
3Y Avg
39.43
5Y Avg
39.43
Market Cap
$1.71B
Price/OCF Ratio
N/A
TTM Avg
11.30
3Y Avg
11.30
5Y Avg
11.30
Market Cap
$2.72B
Price/OCF Ratio
18.63
TTM Avg
24.56
3Y Avg
65.58
5Y Avg
65.58
Market Cap
$470.35M
Price/OCF Ratio
21.33
TTM Avg
23.09
3Y Avg
205.45
5Y Avg
203.38
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.13B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.49B | N/A | 39.43 | 39.43 | 39.43 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 5.44 | 9.24 | 11.01 | 12.44 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A | 11.30 | 11.30 | 11.30 |
| TransMedics Group, Inc. (TMDX)vs › | $2.72B | 18.63 | 24.56 | 65.58 | 65.58 |
| Teladoc Health, Inc. (TDOC)vs › | $1.01B | 3.85 | 4.25 | 5.58 | 12.43 |
| NeoGenomics, Inc. (NEO)vs › | $470.35M | 21.33 | 23.09 | 205.45 | 203.38 |
| NRC Health (NRC)vs › | $459.30M | 15.56 | 15.13 | 16.21 | 19.78 |
| Shoulder Innovations, Inc. (SI)vs › | $389.98M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.24M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
